Share on StockTwits

Shares of GlaxoSmithKline (NYSE:GSK) hit a new 52-week high during mid-day trading on Thursday , ARN reports. The stock traded as high as $55.12 and last traded at $55.08, with a volume of 1,135,278 shares trading hands. The stock had previously closed at $54.81.

A number of analysts have recently weighed in on GSK shares. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Friday, February 7th. They now have a $55.00 price target on the stock. Finally, analysts at S&P Equity Research upgraded shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Monday, January 27th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the stock. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of $88.67.

The stock’s 50-day moving average is $52.96 and its 200-day moving average is $51.94. The company has a market cap of $131.9 billion and a P/E ratio of 15.43.

GlaxoSmithKline (NYSE:GSK) last released its earnings data on Wednesday, February 5th. The company reported $0.30 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.30. The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.84 billion. GlaxoSmithKline’s revenue was up 1.5% compared to the same quarter last year. Analysts expect that GlaxoSmithKline will post $3.73 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.7496 per share. This represents a $3.00 dividend on an annualized basis and a yield of 5.48%. The ex-dividend date of this dividend is Wednesday, February 19th.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.